Every 8-K that ZYNEX INC (ZYXI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ZYXI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZYXI filings page.
Zynex, Inc. has emerged from Chapter 11 protection after a court confirmed reorganization plan became effective on March 26, 2026. As part of the plan, all previously issued equity, including existing common stock and equity awards, was cancelled and extinguished, and 1,000 new common shares were issued to Altivera Medical Holdings LLC, which now owns 100% of the company.
The company entered a new $10.0 million senior secured term loan maturing in 2034, which will convert into common stock once specified payments under a non-prosecution agreement are completed or at maturity. Zynex’s prior $22.3 million DIP facility and $60.0 million convertible notes were discharged. Amended articles now authorize up to 1,000,000 common shares, and new bylaws reset shareholder voting and governance procedures alongside board changes at both the sponsor and company level.
Zynex, Inc. reports that a U.S. bankruptcy court has entered a confirmation order approving its Chapter 11 reorganization plan and disclosure statement. Once conditions are met and the plan becomes effective, all existing equity interests, including the current 30,781,021 common shares, will be cancelled, released and extinguished. Approximately 1,000 new common shares will be issued to an entity owned by the DIP lenders as the plan sponsor, alongside $10 million of takeback debt. The company cautions that trading in its securities is highly speculative and expects existing equity holders to experience a significant loss on their investment if the restructuring transactions are implemented.
Zynex, Inc. reported that the U.S. Securities and Exchange Commission has concluded its investigation and, based on information available, does not intend to recommend an enforcement action against the company. This investigation had been previously disclosed.
The company also reminds investors that its common stock was delisted from Nasdaq following the commencement of voluntary Chapter 11 cases and now trades on the Pink Limited Market under the symbol ZYXIQ. Zynex cautions that trading in its securities during the Chapter 11 process is highly speculative, as the restructuring is expected to cause equity holders to experience a significant loss and the common stock is likely to be cancelled.
Zynex, Inc. entered into a non-prosecution agreement with the U.S. Attorney’s Office for the District of Rhode Island covering past conduct primarily from 2017 to August 2025 under prior management. The company admitted responsibility for acts described in the agreement and related statement of facts.
Under the agreement, Zynex will pay a criminal monetary penalty between $5 million and $12.5 million, depending on earnings and profit through the term, and will forfeit about $85 million in TRICARE billings and about $13 million in other payor billings via release of unpaid claims. Obligations run until the penalty is fully paid or December 31, 2034, whichever is later, and effectiveness is subject to approval by the U.S. Bankruptcy Court in the company’s ongoing Chapter 11 cases.
The company highlights enhanced compliance and governance reforms and ongoing cooperation commitments to authorities. Zynex is in Chapter 11 in the Southern District of Texas, its stock has been delisted from Nasdaq and now trades on the Pink Limited Market under “ZYXIQ,” and it warns that equity holders are expected to experience a significant loss on their investment if its restructuring transactions are implemented.
Zynex, Inc. describes its ongoing Chapter 11 restructuring and recent delisting from Nasdaq. The company and certain subsidiaries have been in voluntary Chapter 11 cases in the Southern District of Texas since December 15, 2025, with the cases jointly administered under a single caption.
On February 7, 2026, Zynex filed a Third Amended Combined Disclosure Statement and Joint Plan of Reorganization, and began soliciting votes on February 9, 2026, with a voting deadline of March 12, 2026. The plan follows a restructuring support agreement and incorporates a global settlement among the company parties, an ad hoc noteholder group and the official committee of unsecured creditors. It contemplates an equity transaction with a plan sponsor selected through a sale process and distribution of any excess sale proceeds under the plan.
Nazdaq determined to delist Zynex’s common stock following the Chapter 11 filings, and the shares were suspended and moved to trade on the Pink Limited Market under the symbol ZYXIQ. Zynex cautions that trading in its securities is highly speculative, states it expects equity holders to experience a significant loss on their investment, and notes the likelihood of cancellation of its common stock in the Chapter 11 process.
Zynex, Inc. provides an update on its ongoing chapter 11 restructuring and related stock exchange status. The company and certain subsidiaries have been operating under voluntary chapter 11 cases in the U.S. Bankruptcy Court for the Southern District of Texas since December 15, 2025.
Zynex has filed a Second Amended Combined Disclosure Statement and Joint Plan of Reorganization that remains consistent with its Restructuring Support Agreement and contemplates an equity transaction with a plan sponsor selected through a sale process. The plan incorporates a Global Settlement among the company parties, an ad hoc noteholder group and the official committee of unsecured creditors.
The plan also establishes a trust for holders of allowed convertible notes claims and general unsecured claims, funded on the plan’s effective date with $750,000 of initial funding, D&O insurance policies and certain estate claims and causes of action. Separately, Zynex notes that its common stock has been delisted from Nasdaq following the chapter 11 filings and now trades on the Pink Limited Market under the symbol ZYXIQ, with deregistration under Section 12(b) to follow effectiveness of Nasdaq’s Form 25. The company cautions that trading in its securities is highly speculative and expects equity holders to experience a significant loss if the restructuring transactions are implemented.
Zynex, Inc. reports key developments in its ongoing Chapter 11 restructuring. The company previously obtained a $22.3 million senior secured debtor-in-possession term loan, available in three draws of $10.15 million, $5.0 million, and $7.15 million, to support operations during bankruptcy. On January 14, 2026, Zynex executed a first amendment to this DIP credit agreement to extend certain milestones tied to the final DIP order, bidding procedures order, and approval of compensation plans, giving more time to advance the court process.
Also on January 14, the company and its affiliated debtors filed a Combined Disclosure Statement and Joint Plan of Reorganization, which follows the terms of an existing restructuring support agreement. The plan contemplates an equity transaction with a “Plan Sponsor” selected through a sale process and provides that any excess sale proceeds will be distributed as outlined in the plan. Zynex cautions that trading in its securities is highly speculative during the Chapter 11 cases and states it expects equity holders to experience a significant loss on their investment if the restructuring transactions are implemented.
Zynex, Inc. has entered into a senior secured debtor-in-possession credit agreement for a $22.3 million term loan to fund its Chapter 11 restructuring. The DIP facility is available in three draws of $10.15 million, $5.0 million and $7.15 million, and carries 10.0% annual interest paid in kind plus substantial fees, including an upfront fee of $669,000, an exit fee of $669,000 and a $5,000,000 backstop fee, along with a minimum 2.00x return on invested capital. The loan matures on the earliest of 105 days after the Chapter 11 filing, an event of default, or completion of a sale of substantially all assets, and is secured by first-priority liens on nearly all of the company’s assets.
Zynex also received notice that Nasdaq will delist its common stock due to the Chapter 11 cases, with trading to be suspended on December 24, 2025; the company does not intend to appeal. Zynex cautions that trading in its securities is highly speculative and states that equity holders are expected to experience a significant loss on their investment if the contemplated restructuring transactions are implemented.
Zynex, Inc. has filed voluntary Chapter 11 cases in the U.S. Bankruptcy Court for the Southern District of Texas, beginning a court-supervised reorganization of the company and certain subsidiaries. The company entered a restructuring support agreement with holders of approximately 80% of its 5.00% Convertible Senior Notes due 2026 and arranged a proposed $22.3 million debtor-in-possession term loan facility bearing 10% annual interest to help fund operations during the process.
The restructuring framework contemplates a competitive sale process under a chapter 11 plan, with the DIP lenders acting as stalking-horse bidder and plan sponsor, and milestones targeting interim and final DIP approval, a bid deadline 75 days after the petition date, an auction (if needed), plan confirmation by 95 days, and emergence by 105 days. The Chapter 11 filing triggered an event of default on approximately $60.0 million principal amount of the convertible notes, though enforcement is stayed under the Bankruptcy Code. The company cautions that trading in its stock is highly speculative and that equity holders are expected to experience a significant loss if the restructuring is completed.
Zynex, Inc. (ZYXI) filed a current report to announce that it released a press release with its financial results for the third quarter of 2025. The press release, dated November 17, 2025, is included as Exhibit 99.1 and is incorporated by reference into the report. The company states that the information in this item, including the press release, is being furnished rather than filed under securities law, which affects how related legal liabilities apply.
Zynex, Inc. reported leadership changes tied to the resignation of Chief Commercial Officer Anna Lucsok. Her resignation was effective October 10, 2025, with separation terms finalized on October 27, 2025.
Under her employment agreement, Ms. Lucsok is entitled to severance, conditioned on her execution, non-revocation, and compliance with a Separation Agreement dated October 27, 2025. The Compensation Committee also approved the accelerated vesting of 60,746 unvested restricted shares previously issued to her, effective as of the Separation Date and subject to the same conditions.
Zynex, Inc. appointed Bret W. Wise to its Board, expanding the board from five to six members effective October 7, 2025. Wise will serve until the 2026 annual meeting and was named Chair of the Audit Committee, and a member of the Compensation and Nominating and Governance Committees.
Director compensation: Wise will receive annual cash retainers of $40,000 (Board), $20,000 (Audit Chair), $7,500 (Compensation Committee), and $5,000 (Nominating and Governance), paid quarterly in arrears and pro‑rated as applicable. He will also receive an initial grant of 20,000 restricted shares and an annual grant of 10,000 restricted shares upon re‑election, vesting quarterly over three years, beginning one quarter after grant, subject to continued service.
Additional updates: Chair Thomas Sandgaard will receive annual retainers of $150,000 (Board Chair) and $250,000 (Technology Committee Chair), paid quarterly in arrears. Chief Commercial Officer Anna Lucsok resigned effective October 10, 2025.
Zynex, Inc. is making a strategic shift for its Zynex Monitoring Solutions (ZMS) business by seeking a commercialization partner for the NiCO™ CO-Oximeter instead of bringing the device to market on its own. As part of this change, the company terminated the positions of a majority of ZMS employees, with substantial cost savings expected from this reduction in force.
Zynex expects pre-tax cash charges of approximately $0.1 million for severance and pre-tax non-cash asset impairment charges of up to approximately $31.0 million, primarily related to goodwill and other assets associated with ZMS. Severance charges are expected to be recognized in the fourth quarter of 2025, and any impairment charges are expected to be recognized in the third quarter of 2025. The company notes there is no assurance it will succeed in attracting a commercialization partner for NiCO™.
Zynex, Inc. reported a leadership role change for one of its senior executives. Effective September 16, 2025, Anna Lucsok transitioned from serving as Chief Operating Officer to serving as the company’s Chief Commercial Officer. She will continue as an executive officer, meaning she remains part of the top management team. As part of this change, her prior responsibilities for overseeing manufacturing, information technology, and regulatory matters were re-allocated within the company to other areas or leaders. The filing does not describe changes to compensation or other terms, focusing instead on clarifying her new commercial-focused role.
Zynex, Inc. appointed Vikram Bajaj as Chief Financial Officer and Treasurer and John Bibb as Chief Legal Officer and Secretary, effective August 18, 2025. Former CFO Dan Moorhead resigned that day and will leave the company on August 29, 2025.
Bajaj and Bibb each receive a $450,000 annual base salary and are eligible for an annual discretionary bonus targeted at 70% of base pay. Each is granted inducement equity awards with a grant date fair value of $2.5 million in restricted stock vesting after three years and $2.5 million in stock options vesting quarterly over four years, subject to continued employment and certain accelerated vesting triggers. They also receive six months of salary and health benefits plus a pro‑rated bonus if terminated without cause or for good reason. The board expanded from four to five members and elected CEO Steven Dyson as a director without additional compensation.
Zynex announced a significant workforce reduction on June 18, 2025, cutting 86 corporate positions, representing 14% of its total workforce. The restructuring is expected to generate $5 million in annualized cost savings.
Key financial impacts include:
- Total restructuring costs estimated at $0.2 million, primarily for employee severance
- Costs to be recognized in Q2 2025
- Majority of payments expected in Q2 and Q3 2025
The company also addressed an ongoing Tricare payment suspension, noting that while they have appealed the temporary suspension, no response has been received. Zynex emphasized that the workforce reduction is part of a planned adjustment in order processing and billing strategy, unrelated to the Tricare situation.